Overview

Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2028-10-01

Target enrollment:

Participant gender:

Summary

This is a prospective, single-arm, multicenter study to observe and evaluate the efficacy and safety of paclitaxel polymeric micelles and carboplatin in combination with iparomilimab and tuvonralimab in neoadjuvant therapy for triple-negative breast cancer. The main endpoint of the study is pCR, 32 patients are scheduled to be enrolled.

Phase:

PHASE2

Details

Lead Sponsor:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Treatments:

Carboplatin